AU2001235838A1 - Imidazol derivatives as raf kinase inhibitors - Google Patents

Imidazol derivatives as raf kinase inhibitors

Info

Publication number
AU2001235838A1
AU2001235838A1 AU2001235838A AU3583801A AU2001235838A1 AU 2001235838 A1 AU2001235838 A1 AU 2001235838A1 AU 2001235838 A AU2001235838 A AU 2001235838A AU 3583801 A AU3583801 A AU 3583801A AU 2001235838 A1 AU2001235838 A1 AU 2001235838A1
Authority
AU
Australia
Prior art keywords
sub
sup
alkyl
optionally substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235838A
Inventor
Jon Graham Steadman
Andrew Kenneth Takle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005387A external-priority patent/GB0005387D0/en
Priority claimed from GB0005370A external-priority patent/GB0005370D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2001235838A1 publication Critical patent/AU2001235838A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I): wherein X is O, CH<SUB>2</SUB>, S or NH, or the moiety X-R<SUP>1 </SUP>is hydrogen; V is CH or N; R<SUP>1 </SUP>is hydrogen, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, aryl, arylC<SUB>1-6</SUB>alkyl, heterocyclyl, heterocyclylC<SUB>1-6</SUB>alkyl, heteroaryl, or heteroarylC<SUB>1-6</SUB>alkyl any of which except for hydrogen may be optionally substituted; R<SUP>2 </SUP>and R<SUP>3 </SUP>independently represent optionally substituted C<SUB>1-6</SUB>alkyl, or R<SUP>2 </SUP>and R<SUP>3 </SUP>together with the carbon atom to which they are attached form an optionally substituted C<SUB>3-7</SUB>cycloalkyl or C<SUB>3-7</SUB>cycloalkenyl ring; or R<SUP>2 </SUP>and R<SUP>3 </SUP>together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R<SUP>4 </SUP>and R<SUP>5 </SUP>independently represent hydrogen, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, aryl, arylC<SUB>1-6</SUB>alkyl, heteroaryl, heteroarylC<SUB>1-6</SUB>alkyl, heterocyclyl, or heterocyclylC<SUB>1-6</SUB>alkyl, any of which except for hydrogen may be optionally substituted or R<SUP>4 </SUP>and R<SUP>5 </SUP>together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X<SUB>1 </SUB>and X<SUB>2 </SUB>is N and the other is NR<SUP>6</SUP>, wherein R<SUP>6 </SUP>is hydrogen, C<SUB>1-6</SUB>alkyl, or arylC<SUB>1-6</SUB>alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them.
AU2001235838A 2000-03-06 2001-03-02 Imidazol derivatives as raf kinase inhibitors Abandoned AU2001235838A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0005387A GB0005387D0 (en) 2000-03-06 2000-03-06 Compounds
GB0005387 2000-03-06
GB0005370 2000-03-06
GB0005370A GB0005370D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000908 WO2001066539A1 (en) 2000-03-06 2001-03-02 Imidazol derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001235838A1 true AU2001235838A1 (en) 2001-09-17

Family

ID=26243806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235838A Abandoned AU2001235838A1 (en) 2000-03-06 2001-03-02 Imidazol derivatives as raf kinase inhibitors

Country Status (8)

Country Link
US (2) US7235658B2 (en)
EP (1) EP1263753B1 (en)
JP (1) JP2003525936A (en)
AT (1) ATE266022T1 (en)
AU (1) AU2001235838A1 (en)
DE (1) DE60103136T2 (en)
ES (1) ES2218391T3 (en)
WO (1) WO2001066539A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005106A (en) 1999-11-22 2002-11-07 Smithkline Beecham Plc Novel compounds.
WO2001066539A1 (en) 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432699A1 (en) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432703A1 (en) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivatives as raf kinase inhibitors
NZ535985A (en) * 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc Methods of promoting osteogenesis
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP1682126B1 (en) 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
TWI387592B (en) 2005-08-30 2013-03-01 Novartis Ag Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis
AR066845A1 (en) 2007-06-05 2009-09-16 Takeda Pharmaceutical DERIVATIVES OF TRIAZOLOPIRIDINE AND IMIDAZOPIRIDINE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2184285B1 (en) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010064611A1 (en) 2008-12-01 2010-06-10 武田薬品工業株式会社 Heterocyclic compound and use thereof
JO3101B1 (en) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD201677A5 (en) * 1980-07-25 1983-08-03 Ciba Geigy PROCESS FOR THE PREPARATION OF TRISUBSTITUTED IMIDAZOLE DERIVATIVES
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL123950A (en) * 1995-10-06 2001-04-30 Merck & Co Inc Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP3418624B2 (en) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド Substituted imidazoles having cytokine inhibitory activity
EP1049664B1 (en) 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
KR20010025087A (en) 1998-05-22 2001-03-26 스튜어트 알. 수터 Novel 2-Alkyl Substituted Imidazole Compounds
US6691178B1 (en) * 2000-02-22 2004-02-10 Stmicroelectronics, Inc. Fencepost descriptor caching mechanism and method therefor
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2001066539A1 (en) 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors
EP1318992B1 (en) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
JP4217480B2 (en) 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション New compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432699A1 (en) 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
EP1423383B1 (en) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
EP1432703A1 (en) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
ES2218391T3 (en) 2004-11-16
DE60103136D1 (en) 2004-06-09
US20060122207A1 (en) 2006-06-08
JP2003525936A (en) 2003-09-02
US7235658B2 (en) 2007-06-26
WO2001066539A1 (en) 2001-09-13
EP1263753B1 (en) 2004-05-06
DE60103136T2 (en) 2004-10-28
EP1263753A1 (en) 2002-12-11
ATE266022T1 (en) 2004-05-15
US20030153588A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
MXPA02011974A (en) Substituted quinazoline derivatives and their use as inhibitors.
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
DE60128343D1 (en) PYRIMIDINE COMPOUNDS
EE200200148A (en) Quinazoline derivatives, methods for their preparation and their use
TW200611907A (en) Fused heterocyclic compound
ATE164575T1 (en) SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS
RU2007110629A (en) DNA-PC INHIBITORS
TW200612920A (en) Novel imidazolidine derivatives
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
HUP0400246A2 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
ATE403653T1 (en) PYRIDINE-SUBSTITUTED FURAN DERIVATIVES AS RAF-KINASE INHIBITORS
WO2004004730A3 (en) 2-aminopyrazine derivatives as inhibitors of cyclin dependent kinases for the treatment of proliferative disorders
MX2023010125A (en) Cardiac sarcomere inhibitors.
SE0201658D0 (en) Immediate release pharmaceutical formulation
UA74341C2 (en) Borelydine derivatives inhibiting angiogenesis
DK1899331T3 (en) Homomorpholinoxazolidones as antibacterial agents
HRP20050617A2 (en) Imidazol derivatives having affinity for alpha 2 receptors activity
ATE247662T1 (en) INDOLOCARBAZOLE ALKALOIDS FROM A MARINE ACTINOMYCETE
GB0114699D0 (en) Organic compounds
MX2008002753A (en) Pyridazinone derivatives used for the treatment of pain.